MAIA Biotechnology CEO Vitoc Vlad bought 73,000 shares at $1.37 per share, and the transaction represented about 7.0% of his resulting position. His reported holding after the purchase was 1,049,121 shares, giving investors a precise view of the executive’s changed stake in MAIA Biotechnology.
Key Highlights
- The transaction was recorded on Sep. 14, 2026, under Form 4 transaction code P.
- Vitoc Vlad’s resulting holding totaled 1,049,121 shares.
- The purchase represented about 7.0% of Vlad’s resulting shares holding.
MAIA Biotechnology, Inc. (AMEX: MAIA) Chief Executive Officer Vitoc Vlad bought 73,000 shares at $1.37 per share. The transaction left Vlad with 1,049,121 shares and represented about 7.0% of his resulting holding.
September 14 Purchase Classified as Code P
The transaction took place on Sep. 14, 2026. Its Form 4 transaction code was P, which identifies an open-market purchase. The per-share price was $1.37. The reported transaction involved 73,000 shares of MAIA Biotechnology.
FAQs
Q: How many MAIA Biotechnology shares did Vitoc Vlad buy?
A: Vitoc Vlad bought 73,000 MAIA Biotechnology shares in the reported transaction. The filing stated that the purchase price was $1.37 per share.
Q: What was Vitoc Vlad’s resulting holding in MAIA Biotechnology?
A: Vitoc Vlad’s reported holding after the transaction was 1,049,121 shares of MAIA Biotechnology. The Form 4 identified Vlad as the company’s chief executive officer in connection with the purchase.
Q: When did the MAIA Biotechnology CEO share purchase occur?
A: The transaction occurred on Sep. 14, 2026, according to the Form 4 filing. The filing listed transaction code P, identifying the purchase as an open-market transaction.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.